CPA
GDRX icon

Capital Performance Advisors’s GoodRx Holdings GDRX Stock Holding History

Capital Performance Advisors’s Portfolio GDRX Stock Details GDRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-20
Closed -$139 – 1123
2024
Q3 		$139 Buy
+20
New +$157 ﹤0.01% 2638

Other funds holding GDRX

FPM
Francisco Partners Management San Francisco, California $292M AUM 34.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
LCM
Lakewood Capital Management New York $1.58B AUM 0.92% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
SLG
Silver Lake Group Menlo Park, California $3.68B AUM 7.22% 1-Year Est. Return
PTC
Petrus Trust Company Dallas, Texas $915M AUM 2.95% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RRCP
Rip Road Capital Partners Boston, Massachusetts $62.5M AUM 1.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Capital Performance Advisors's GDRX Position: Q4 2024 in Review

Capital Performance Advisors sold out of GoodRx Holdings (GDRX) in Q4 2024, closing a stake of 20 shares — an estimated $139 sold.

Capital Performance Advisors first reported a position in GDRX in Q3 2024 and held it in 1 quarter. The position peaked at $139 in Q3 2024. 170 funds tracked by Wall St. Rank hold GDRX as of Q4 2024.

  • Capital Performance Advisors reported no remaining GoodRx Holdings position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 20 GoodRx Holdings shares in Q4 2024, an estimated $139.
  • Capital Performance Advisors first reported a position in GoodRx Holdings in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's GoodRx Holdings position peaked at $139 in Q3 2024.
  • 170 funds tracked by Wall St. Rank held GoodRx Holdings as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.